Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Financing Activities (2017 - 2026)

Ovid Therapeutics filings provide 11 years of Cash from Financing Activities readings, the most recent being $89.0 million for Q1 2026.

  • Quarterly Cash from Financing Activities rose 684376.92% to $89.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $164.2 million through Mar 2026, up 40238.08% year-over-year, with the annual reading at $75.2 million for FY2025, 11991.16% up from the prior year.
  • Cash from Financing Activities hit $89.0 million in Q1 2026 for Ovid Therapeutics, up from $75.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $89.0 million in Q1 2026 and bottomed at -$43599.0 in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $13.0 million, with a median of $109549.0 recorded in 2022.
  • The largest annual shift saw Cash from Financing Activities crashed 139.93% in 2022 before it skyrocketed 684376.92% in 2026.
  • Ovid Therapeutics' Cash from Financing Activities stood at -$43599.0 in 2022, then soared by 68984.61% to $30.0 million in 2023, then tumbled by 99.87% to $38000.0 in 2024, then skyrocketed by 197739.47% to $75.2 million in 2025, then rose by 18.36% to $89.0 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Cash from Financing Activities are $89.0 million (Q1 2026), $75.2 million (Q4 2025), and $15000.0 (Q3 2025).